2022
Understanding What Matters to Myelodysplastic Syndrome Patients - a Study of Preferences for Treatments with Hypomethylating Agents
Zeidan A, Tsai S, Karimi M, Schmier J, Jayade S, Zormpas E, Hassan A, Ruiters D, Anthony C, Hill K, Wert T, Botteman M. Understanding What Matters to Myelodysplastic Syndrome Patients - a Study of Preferences for Treatments with Hypomethylating Agents. Blood 2022, 140: 10847-10848. DOI: 10.1182/blood-2022-167360.Peer-Reviewed Original ResearchPoster: MDS-529 The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups
Alrawabdeh J, Alzu'bi M, Hamadneh Y, Odeh N, Alzyoud M, Awidi A, Magableh A, Alshorman A, Al-Fararjeh F, Aladily T, Zeidan A, Bawa'neh H. Poster: MDS-529 The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s154. DOI: 10.1016/s2152-2650(22)00945-4.Peer-Reviewed Original Research
2020
The Direct Medical Costs of Treatment Discontinuation Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents
Joshi N, Kale H, Corman S, Hill K, Wert T, Zeidan A. The Direct Medical Costs of Treatment Discontinuation Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents. Blood 2020, 136: 17-18. DOI: 10.1182/blood-2020-139642.Peer-Reviewed Original ResearchNon-persistent groupHealthcare resource useDirect medical costsHigh-risk myelodysplastic syndrome (MDS) patientsHR-MDS patientsNon-persistent patientsMyelodysplastic syndrome patientsHMA treatmentCurrent equity holderMedical costsHR-MDSPersistent patientsSyndrome patientsPropensity score-based inverse probabilityContinuous Medicare enrollmentTotal PPPM costsEnd Results-MedicareStem cell transplantRetrospective cohort designHealthcare spendingLoss of responseSubstantial cost burdenHospice care useCurrent employmentER costs
2015
Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine
Zeidan AM, Ali N, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Clinical Lymphoma Myeloma & Leukemia 2015, 15: 705-710. PMID: 26440749, DOI: 10.1016/j.clml.2015.08.083.Peer-Reviewed Original ResearchConceptsLower-risk myelodysplastic syndromesFirst-line therapyErythropoiesis-stimulating agentsFailure of treatmentTreatment failureInternational Working Group 2006 criteriaResponse rateSecond-line therapyMyelodysplastic syndrome patientsHigh response rateChromosome 5q deletionAzacitidine useHematologic improvementLenalidomide treatmentOverall survivalAnemic patientsMyelodysplastic syndromeSyndrome patientsLarge cohortLenalidomideAzacitidinePatientsLeukemic progressionClinical databaseTherapyGenome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?
Lee EJ, Zeidan AM. Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy? Expert Review Of Hematology 2015, 8: 155-158. PMID: 25697572, DOI: 10.1586/17474086.2015.1016905.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeHigh-risk myelodysplastic syndromeMolecular mutationsRecurrent molecular mutationsReliable clinical predictorsIndependent prognostic valueMyelodysplastic syndrome patientsUrgent clinical needIdentification of biomarkersAgent therapyClinical predictorsPrognostic valuePrognostic subgroupsSyndrome patientsVariable coursePatientsClinical implicationsTET2 mutationsClinical needSyndromeTherapyRecurrent mutationsBiomarkersHMAsResearch priorities